
|
![]() ![]() ![]() ![]() ![]() ![]()
维梧生技创业投资管理公司(Vivo
Ventures)一直专注于生命科学领域的投资,其投资对象主要集中在美国和大中华地区。自创建以来,维梧生技不仅成为美国最早投资中国企业的生命科学风险投资基金之一,并且还积极将美国公司引进到大中华市场,寻求双方的蓬勃发展和在科学,技术,商业,市场的尖端合作与交流。
|
新闻 China Kanghui Holdings Announces Pricing of Initial Public Offering FDA Approves Sagent Pharmaceuticals, Inc.'s Heparin Sodium Injection, USP Vicept Therapeutics Secures $10 Million to Complete Series A Funding; Company to Develop Lead Product for Rosacea and Other Topical Agents for the Treatment of Skin Disorders Dynavax Raises $44 Million Through Public Offering of Common Stock and Warrants Sagent Pharmaceuticals Raises $40 Million in Two Tranches of a Series B Financing |